Treatment of Upper Extremity Deep Vein Thrombosis (DVT)

Principal Investigator: Suman Rathbun, MD

OBJECTIVE: 

To document the long-term outcome (prognosis) of patients diagnosed with upper extremity deep-vein thrombosis (DVT) who are treated with Fragmin (dalteparin sodium injection) followed by Warfarin for 3 months.

Specific Aims:

1.  To evaluate the incidence of recurrent venous thromboembolism in patients diagnosed with upper extremity DVT who are treated with Fragmin followed by Warfarin for 3 months.

2.  To evaluate the incidence of major bleeding in patients diagnosed with upper extremity DVT who are treated with Fragmin followed by Warfarin for 3 months.

3.  To evaluate the incidence of post-phlebitic syndrome at one year in patients with upper extremity DVT.

4.  To gather descriptive/demographic data on patients with upper extremity DVT.

5.  To perform a pharmacoeconomic assessment of treatment of upper extremity DVT using low molecular weight heparin.

Participant Inclusion Criteria:

Participant Compensation:

1. Patients diagnosed with upper extremity deep-vein thrombosis (DVT)

Contact:

Penny Razo-Mosier, LPN. (405) 271-4742  email penny-razo-mosier@ouhsc.edu